[1]CurrentPatentAssignee:ASTELLASPHARMAINC-WO2011/5909,2011,A2
[1]CurrentPatentAssignee:ASTELLASPHARMAINC-WO2011/5909,2011,A2Locationinpatent:Page/Pagecolumn14-15
[1]CurrentPatentAssignee:ASTELLASPHARMAINC-WO2011/5909,2011,A2
[1]CurrentPatentAssignee:ASTELLASPHARMAINC-WO2011/5909,2011,A2
Title: Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.
Journal: Journal of medicinal chemistry 20110310
Title: Falcon BL, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res. 2011 Mar 1;71(5):1573-83.
Title: Mateo J, et al. A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. Br J Cancer. 2016;114(8):889-896.
Title: Zhang Y, et al. PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer. EBioMedicine. 2015 Nov 19;2(12):1944-56.
Title: Zhi X, et al. OSI-027 modulates acute graft-versus-host disease after liver transplantation in a rat model. Liver Transpl. 2017 Sep;23(9):1186-1198.